Inclusion Criteria:

- Written informed concent

- Age at least 18 years

- WHO Performance status 0-3

- Histologically verified B-cell lymphoma

- Diffuse large B-cell lymphoma and follicular grade III, failing an anthracycline
containing regimen and patients not found suitable for a second line chemotherapy
consolidated by high dose chemotherapy (HDCT) with stem cell support or radiotherapy

- Transformed B-cell lymphoma, failing first line therapy and not suitable for high
dose chemotherapy (HDCT) or with a history of HDCT with stem cell support

- Follicular lymphoma grade II and I, and other indolent lymphomas must have failed
second line treatment.

- One of these treatments must have contained chemotherapy and rituximab, the latter
either together with chemotherapy or as maintenance.

- The lymphoma must require treatment, Mantle cell lymphoma, failing first line
treatment,treatment required

- Measurable disease and the tumor burden must be acceptable according to the
investigator

- Radiological studies must be performed and a unilateral bone marrow biopsy within 4
weeks before start of treatment

- Bone marrow reserve likely to give a harvest of at least 2x10 6 peripheral CD34+
stemcells or the existence of such a harvest or a corresponding central harvest

- Total bilirubin should not exceed 40 micromole/L

- A GFR as measured by Cystatin C of 50 ml/min

- HIV, Hepatitis B and C status known

- Life expectancy of at least 3 months.

Exclusion Criteria:

- Known or clinical evidence of CNS involvement

- Bone marrow involvement at harvest as measured by biopsy and flow cytometry

- Subjects with prior radiation to a field that includes over or equal 25% of their red
marrow, liver or lung or to both kidneys

- Prior chemotherapy or radiotherapy within 4 weeks

- Subjects who are pregnant or nursing

- Pulmonary involvement, that is not negligible at the discretion of the investigator

- Liver involvement of lymphoma

- History of hepatitis B or C.